MTOR and cancer: We assessed the effects of an Akt1/2 inhibitor and the mTOR inhibitor, everolimus, which is a Food and Drug Administration-licensed drug for use in a number of cancers (37) and acts on the Akt pathway (38), on pAkt and proliferation responses in cells expressing the WT PRLR (Supplementary Material, Fig. S3) and mutant Asn492Ile PRLR (Fig. 7).